Researchers developed a novel peptide, KS-133, to target cognitive dysfunction in schizophrenia. By using a brain-targeting peptide, KS-487, they successfully transported KS-133 across the blood-brain barrier. Their nanoparticle-based drug delivery system improved cognitive functions in mice, offering a new therapeutic strategy.
Peptide Improves Cognition in Schizophrenia
![](http://sshop.me/wp-content/uploads/2024/06/schizophrenia-peptide-cognition-neurosiceince-1155x770-1.jpg)